Skip to main content

anti-cd19/anti-cd3/anti-cd2 trispecific antibody pit565

Generic: Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565

anti-cd19/anti-cd3/anti-cd2 trispecific antibody pit565: 3 clinical trials tracked.

anti-cd19/anti-cd3/anti-cd2 trispecific antibody pit565 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-cd19/anti-cd3/anti-cd2 trispecific antibody pit565, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Rheumatoid Arthritis

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)

NCT07029555Registry updated 2026-06-30·Phase 1
Active, not recruiting

Primary endpoint: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen57 targetStarted 2025-06Completion 2028-0516 sites · Argentina, Bulgaria, China, France…Novartis Pharmaceuticals

A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979Registry updated 2026-06-30·Phase 1
Active, not recruiting

Primary endpoint: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

Interventionalopen54 targetStarted 2024-10Completion 2027-1111 sites · China, Germany, Hungary, Netherlands…Novartis Pharmaceuticals

A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies

NCT05397496Registry updated 2026-07-28·Phase 1
Active, not recruiting

Primary endpoint: Incidence and severity of Dose Limiting Toxicities (DLTs)

Interventionalopen61 enrolledStarted 2022-10Completion 2027-0118 sites · Belgium, China, France, Israel…Novartis Pharmaceuticals